199 related articles for article (PubMed ID: 37328052)
1. Immunotherapy and immunoevasion of colorectal cancer.
Al Zein M; Boukhdoud M; Shammaa H; Mouslem H; El Ayoubi LM; Iratni R; Issa K; Khachab M; Assi HI; Sahebkar A; Eid AH
Drug Discov Today; 2023 Sep; 28(9):103669. PubMed ID: 37328052
[TBL] [Abstract][Full Text] [Related]
2. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in colorectal cancer.
Agarwal P; Le DT; Boland PM
Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
[TBL] [Abstract][Full Text] [Related]
4. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.
Chen L; Jiang X; Li Y; Zhang Q; Li Q; Zhang X; Zhang M; Yu Q; Gao D
Clin Immunol; 2022 Apr; 237():108962. PubMed ID: 35227870
[TBL] [Abstract][Full Text] [Related]
5. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
6. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
7. Cell-based immunotherapy approaches for colorectal cancer: main achievements and challenges.
Shahnazari M; Samadi P; Pourjafar M; Jalali A
Future Oncol; 2021 Aug; 17(24):3253-3270. PubMed ID: 34156258
[TBL] [Abstract][Full Text] [Related]
8. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment.
Zheng Z; Wieder T; Mauerer B; Schäfer L; Kesselring R; Braumüller H
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511431
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy.
Yang Y; Meng WJ; Wang ZQ
Front Biosci (Landmark Ed); 2023 Apr; 28(4):69. PubMed ID: 37114536
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer.
Yu I; Dakwar A; Takabe K
Cells; 2023 Jan; 12(2):. PubMed ID: 36672193
[TBL] [Abstract][Full Text] [Related]
11. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
Quiroga D; Lyerly HK; Morse MA
Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
[TBL] [Abstract][Full Text] [Related]
12. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
[TBL] [Abstract][Full Text] [Related]
13. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
[TBL] [Abstract][Full Text] [Related]
14. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
Front Immunol; 2021; 12():808964. PubMed ID: 35095898
[TBL] [Abstract][Full Text] [Related]
16. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer.
Wu C; Shao Y; Gu W
Clin Transl Oncol; 2023 Jul; 25(7):1916-1928. PubMed ID: 36717514
[TBL] [Abstract][Full Text] [Related]
18. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy.
Kamal Y; Schmit SL; Frost HR; Amos CI
Immunotherapy; 2020 Oct; 12(14):1083-1100. PubMed ID: 32787587
[TBL] [Abstract][Full Text] [Related]
19. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
Aristin Revilla S; Kranenburg O; Coffer PJ
Front Immunol; 2022; 13():903564. PubMed ID: 35874729
[TBL] [Abstract][Full Text] [Related]
20. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?
Vegivinti CTR; Gonzales Gomez C; Syed M; Ferrell M; Cheng S; Singhi A; Saeed A; Sahin IH
Expert Opin Biol Ther; 2023; 23(7):595-601. PubMed ID: 37318031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
